Eliminating Right-to-Left Shunt With Patent Foramen Ovale Closure Not as Simple as it Seems⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Rogers, Jason H. & Smith, Thomas W.
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liminating Right-to-Left
hunt With Patent Foramen
vale Closure
ot as Simple as it Seems*
ason H. Rogers, MD, Thomas W. Smith, MD
acramento, California
atent foramen ovale (PFO) is associated with numerous
linical conditions, such as cryptogenic stroke, paradoxical
mbolism, migraine headaches, decompression illness, and
hunt-related hypoxemia. As a result, transcatheter closure
f PFO has become relatively common, driven by the
pparent ease of the procedure, patient and clinician pref-
rence over medical therapy, and numerous retrospective
nalyses demonstrating clinical benefit. The procedure is
erformed under conscious sedation and, in experienced
ands, can been done routinely in under 30 min. The fact
hat there have been no large prospective randomized trials
o prove the efficacy of PFO closure has done little to
issuade the enthusiastic use of closure devices.
See page 561
The immediate and long term goal of transcatheter PFO
losure is elimination of right-to-left shunt (RLS) through
he interatrial septum. When detected, RLS is generally
econdary to an atrial level shunt (i.e., PFO), but noncardiac
LS (primarily intrapulmonary) has also been implicated in
he pathophysiology of clinical conditions resulting from
aradoxical embolism (1). Intrapulmonary RLS can coexist
ith PFO and in some cases can be mistaken as a source of
LS in a patient presumed to have a PFO. For instance, in
he MIST (Migraine Intervention With STARFlex Tech-
ology) trial, 5 of the 74 patients with RLS randomized to
FO closure actually had no PFO found at the time of the
rocedure. The cause of the RLS in these patients was
resumably due to an intrapulmonary shunt (2). The pres-
nce of coexisting intrapulmonary shunting would clearly
ave major implications when designing trials to assess the
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.a
From the Division of Cardiovascular Medicine, University of California Davis
edical Center, Sacramento, California.fficacy of PFO closure to eliminate RLS. Methods to
dentify these confounding patients have not been well-
escribed in published reports to date.
Jesurum et al. (3), in this issue of JACC: Cardiovascular
nterventions, describe a novel method to assess the preva-
ence of secondary (intrapulmonary) RLS in patients under-
oing transcatheter closure of PFO. During sizing-balloon
nflation within the PFO (and presumed occlusion of the
FO due to lack of color flow seen with intracardiac
chocardiography [ICE] around the balloon), agitated sa-
ine was injected into the inferior vena cava with calibrated
espiratory strain, followed by assessment of RLS via trans-
ranial Doppler (TCD). If 10 embolic tracks were de-
ected, this was defined as a “secondary RLS.” After PFO
losure, residual RLS was assessed immediately with agi-
ated saline and TCD and in late follow-up with TCD and
ransthoracic echocardiography. This study demonstrated
hat those subjects with RLS during balloon inflation
secondary RLS) were significantly more likely to have RLS
uring immediate and late follow-up when compared with
hose patients without RLS during balloon inflation. Pa-
ients with secondary RLS also had more atrial septal
neurysms (p  NS) and significantly larger PFO waist
iameters than those without secondary RLS (p  0.013).
ith these data, the authors concluded that ICE, TCD,
nd balloon occlusion can be used to detect secondary RLS
uring PFO closure.
The overall concept of this report is novel, because there
ave been no previous reports using this technique (or any
ther for that matter) to assess the prevalence of secondary
LS during PFO closure. The authors are to be congratu-
ated for attempting to broaden our understanding of RLS
hysiology in a PFO-closure population. However, as with
ll complex questions, the devil is ever present in the details.
irst, the title and claim that persistent shunt after balloon
cclusion or in follow-up is due to a “secondary source of
LS” is presumptive. Certainly, some of the patients might
ave a coexisting intrapulmonary shunt. However, another
uite plausible explanation is that those patients with
econdary RLS at baseline actually had incomplete occlu-
ion of the PFO with the sizing-balloon. Even in the
bsence of color flow on ICE, it might be impossible to rule
ut small areas on the edge of the balloon (or associated
icrofenestrations) where bubbles could cross. Also, the
alloon might appear occlusive at rest although not be
cclusive with increased right-sided pressure during respi-
atory strain. The fact that the secondary RLS group had
ore atrial septal aneurysms and a larger balloon waist
iameter would also suggest that incomplete balloon occlu-
ion of large, floppy PFOs is a more likely source of RLS
han an intrapulmonary etiology.
Improved methodology might include the use of trans-
sophageal echocardiography or other imaging of the left
trium and pulmonary veins during balloon occlusion of the
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569FO, in an effort to document that bubbles emanate from
of the pulmonary veins and not from the interatrial
eptum. At follow-up, the authors did not comment on the
iming of the appearance of saline contrast in the left atrium
s assessed by transthoracic echocardiography. Whereas
here are data showing that pulmonary arteriovenous mal-
ormations (PAVMs) and intracardiac RLS do overlap in
he time delay during which the bubbles appear in the left
trium (4), one might expect a trend toward earlier detec-
ion in those with persistent cardiac shunts. Documenting
AVMs with pulmonary angiography in patients with large
econdary RLS would add strength to the authors’ conclu-
ions. The majority of PFO closures in this series were
erformed with the CardioSEAL device, and the high
ersistence of late shunt (44%) in those subjects without
econdary RLS suggests that at least some of the persistence
f late shunt is device-related and not intrapulmonary.
inally, the clinical significance of these secondary shunts
emains unclear, because this study was not powered to
valuate clinical event rates in the 2 groups.
In conclusion, Jesurum et al. (3) report that secondary
LS are common (20%) in patients referred for transcath-
ter PFO closure. This would make intrapulmonary shunt-
ng almost as common as PFOs are in the normal popula-
ion. If PAVMs, albeit small, are actually this common,
hen that finding is in itself new and unexpected. In an
utopsy study from Johns Hopkins Hospital, only 3
AVMs were detected in 15,000 consecutive autopsies (5).
any of the angiographic studies of PAVMs have been
one in referral centers for hereditary hemorrhagic telangi-
ctasia, a very different population from that in this study
6). If patients undergoing PFO closure have coexisting antrapulmonary shunts, this might well have significant
linical implications. Further refinements in screening and
ethodology should one day allow clinicians to readily
dentify these individuals. As our understanding in this field
volves, PFO closure might not remain as simple an option
s it seems today.
eprint requests and correspondence: Dr. Jason H. Rogers,
ivision of Cardiovascular Medicine, 4860 Y Street, Suite 2820,
acramento, California 95817. E-mail: jason.rogers@ucdmc.
cdavis.edu.
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